Markets:

Overview

News

Currencies

International

Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.430 -0.010 (-0.69%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Apple, Amazon, HP And Other Big Losers From Friday ↗

August 29, 2022

U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday ↗

August 29, 2022

Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.

Via Benzinga

What 5 Analyst Ratings Have To Say About Allogene Therapeutics ↗

August 10, 2022

Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022 ↗

August 10, 2022

Via Benzinga

Allogene Therapeutics: Q2 Earnings Insights ↗

August 09, 2022

Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

July 27, 2022

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗

July 20, 2022

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022 ↗

July 15, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 15, 2022

Via Benzinga

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗

June 03, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About Allogene Therapeutics ↗

June 03, 2022

Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 17, 2022

Via Benzinga

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data ↗

May 10, 2022

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

U.S. FDA Grants Orphan-Drug Designation for Allogene's ALLO-605 for multiple myeloma ↗

April 27, 2022

Allogene Therapeutics, Inc. (Nasdaq: ALLO) received Orphan-drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its drug candidate ALLO-605 for the treatment of patients with...

Via Benzinga

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗

April 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030

April 21, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from...

Via FinancialNewsMedia

Allogene's Preclinical Data Show Healthy Donor-Derived Allogeneic CAR T Cells Have Better Immune Fitness, Killing Activity ↗

March 23, 2022

Allogene Therapeutics Inc (NASDAQ: ALLO) announced the

Via Benzinga

Recap: Allogene Therapeutics Q4 Earnings ↗

February 23, 2022

Allogene Therapeutics (NASDAQ:ALLO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

Allogene Therapeutics Earnings Preview ↗

February 22, 2022

Allogene Therapeutics (NASDAQ:ALLO) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement....

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

February 16, 2022

On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low...

Via Benzinga

FDA Lifts Clinical Hold On Allogene's CAR-T Trials ↗

January 11, 2022

The FDA has lifted the hold on Cellectis SA's (NASDAQ: CLLS) licensed partner, Allogene Therapeutics Inc (NASDAQ: ALLO) clinical trials. The...

Via Benzinga

Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗

January 10, 2022

Pfizer and Bayer inked deals with several companies in gene-editing.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 20, 2021

Gainers Intra-Cellular Therapies (NASDAQ:ITCI) stock rose 18.79% to $46.52 during Monday's pre-market session. The market value of their outstanding shares is at $3.7...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 13, 2021

Gainers Arena Pharmaceuticals (NASDAQ:ARNA...

Via Benzinga

58 Biggest Movers From Yesterday ↗

December 14, 2021

Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-...

Via Benzinga

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗

December 12, 2021

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple...

Via Benzinga

Being First Is Not Enough For Crispr Therapeutics ↗

November 15, 2021

CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.

Via InvestorPlace

Allogene Therapeutics Inc (ALLO) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

ALLO earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

All News about Allogene Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today